Patient characteristics
Patient characteristic . | DR15-, no. (%) . | DR15+, no. (%) . | P . |
|---|---|---|---|
| No. patients | 132 | 35 | NS |
| Males | 83 (63) | 21 (60) | NS |
| KPS | NS | ||
| 80% or less | 47 (36) | 10 (29) | |
| 90% to 100% | 85 (64) | 25 (71) | |
| Diagnosis | NS | ||
| AML | 69 (52) | 15 (43) | |
| CML | 51 (39) | 12 (34) | |
| MDS | 12 (9) | 8 (23) | |
| Disease status at transplantation | NS | ||
| CR | 31 (23) | 5 (14) | |
| Other | 101 (77) | 30 (86) | |
| Conditioning regimen | NS | ||
| VpCyTBI | 69 (52) | 15 (43) | |
| BuTBI | 23 (17) | 4 (11) | |
| BuCy | 15 (11) | 7 (20) | |
| CyTBI | 9 (7) | 4 (11) | |
| Other | 16 (12) | 5 (14) | |
| TBI based | NS | ||
| Yes | 105 (80) | 26 (74) | |
| No | 27 (20) | 9 (26) | |
| Donor | NS | ||
| Related | 93 (70) | 26 (74) | |
| Unrelated | 39 (30) | 9 (26) | |
| Recipient-donor sex | NS | ||
| Matched | 75 (57) | 16 (46) | |
| Mismatched | 53 (40) | 19 (54) | |
| Not recorded | 4 (3) | 0 | |
| HLA-DR typing | .03 | ||
| DNA | 80 (61) | 28 (80) | |
| Serologic | 52 (39) | 7 (20) | |
| GVHD prophylaxis | .03 | ||
| CsA or FK + Mtx | 55 (42) | 18 (51) | |
| CsA or FK + Mtx + Mp | 56 (42) | 9 (26) | |
| CsA + Mp | 12 (9) | 1 (3) | |
| CsA + OKT3 + Mp | 4 (3) | 5 (14) | |
| Other | 5 (4) | 2 (6) |
Patient characteristic . | DR15-, no. (%) . | DR15+, no. (%) . | P . |
|---|---|---|---|
| No. patients | 132 | 35 | NS |
| Males | 83 (63) | 21 (60) | NS |
| KPS | NS | ||
| 80% or less | 47 (36) | 10 (29) | |
| 90% to 100% | 85 (64) | 25 (71) | |
| Diagnosis | NS | ||
| AML | 69 (52) | 15 (43) | |
| CML | 51 (39) | 12 (34) | |
| MDS | 12 (9) | 8 (23) | |
| Disease status at transplantation | NS | ||
| CR | 31 (23) | 5 (14) | |
| Other | 101 (77) | 30 (86) | |
| Conditioning regimen | NS | ||
| VpCyTBI | 69 (52) | 15 (43) | |
| BuTBI | 23 (17) | 4 (11) | |
| BuCy | 15 (11) | 7 (20) | |
| CyTBI | 9 (7) | 4 (11) | |
| Other | 16 (12) | 5 (14) | |
| TBI based | NS | ||
| Yes | 105 (80) | 26 (74) | |
| No | 27 (20) | 9 (26) | |
| Donor | NS | ||
| Related | 93 (70) | 26 (74) | |
| Unrelated | 39 (30) | 9 (26) | |
| Recipient-donor sex | NS | ||
| Matched | 75 (57) | 16 (46) | |
| Mismatched | 53 (40) | 19 (54) | |
| Not recorded | 4 (3) | 0 | |
| HLA-DR typing | .03 | ||
| DNA | 80 (61) | 28 (80) | |
| Serologic | 52 (39) | 7 (20) | |
| GVHD prophylaxis | .03 | ||
| CsA or FK + Mtx | 55 (42) | 18 (51) | |
| CsA or FK + Mtx + Mp | 56 (42) | 9 (26) | |
| CsA + Mp | 12 (9) | 1 (3) | |
| CsA + OKT3 + Mp | 4 (3) | 5 (14) | |
| Other | 5 (4) | 2 (6) |
Median age was 43 years (range, 11-66 years) for DR15- patients and 42 years (range, 11-62 years) for DR15+ patients.
DR15- indicates no alleles for 15 at DRB1; DR15+, 1 or 2 alleles for 15 at DRB1; NS, not significant (P > .1); KPS, Karnofsky performance status; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; and CR, complete remission.